

Appendix: Tables

1.	Sales January to March 2025 and 2024	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2025 vs. YTD March 2024	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to March 2025 and 2024

CHF millions	Three months ended 31 March		% change	
	2025	2024	At CER	In CHF
Pharmaceuticals Division	11,949	10,921	8	9
United States	6,224	5,692	6	9
Europe	2,320	2,200	5	5
Japan	671	649	3	3
International	2,734	2,380	18	15
Diagnostics Division	3,491	3,478	0	0
Roche Group	15,440	14,399	6	7

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Pharmaceuticals Div.	10,921	2	11,716	9	11,620	10	11,914	12	11,949	8
United States	5,692	5	6,190	6	6,284	9	6,608	15	6,224	6
Europe	2,200	11	2,225	10	2,188	2	2,219	10	2,320	5
Japan	649	-45	717	-3	717	1	791	1	671	3
International	2,380	12	2,584	23	2,431	22	2,296	11	2,734	18
Diagnostics Division	3,478	2	3,733	8	3,516	6	3,597	-1	3,491	0
Roche Group	14,399	2	15,449	9	15,136	9	15,511	9	15,440	6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

Rozlytrek	40	36	14	12	5	7	2	-10	19	83
Luxturna	35	*	35	*	-	-	-	-	-	-
Lunsumio	21	25	14	6	6	89	-	-	1	408
Itovebi	14	-	14	-	-	-	-	-	-	-
Cotellic	12	23	6	51	3	-11	-	-	3	21
Piasky	9	-	-	-	1	-	7	-	1	-
Susvimo	2	171	2	171	-	-	-	-	-	-
Ronapreve	-	-100	-	-	-	-100	-	-	-	-100
Pharma other	629	-12	144	-13	108	-9	105	3	272	-16
Pharma total sales	11,949	8	6,224	6	2,320	5	671	3	2,734	18

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Ocrevus	1,658	8	1,701	9	1,697	11	1,688	7	1,778	6
Hemlibra	1,040	8	1,103	6	1,137	14	1,223	21	1,165	11
Vabysmo	847	108	947	81	1,022	59	1,048	43	1,018	18
Tecentriq	865	1	933	2	905	0	937	-1	870	0
Perjeta	936	-3	985	-1	888	2	807	9	840	-10
Xolair	496	10	614	11	627	12	733	29	645	26
Actemra/RoActemra	618	-2	658	8	672	7	697	4	619	-1
Phesgo	388	70	411	52	445	55	496	72	593	52
Kadcyla	483	3	516	9	495	7	504	9	506	5
Evrysdi	356	7	482	42	408	13	385	10	420	18
Alecensa	355	4	411	10	385	7	397	8	397	11
Polivy	250	81	263	34	304	24	304	34	358	42
MabThera/Rituxan	351	-18	355	-15	317	-14	356	-2	298	-16
Activase/TNKase	296	4	297	-7	302	9	307	15	297	-2
Herceptin	364	-17	376	-4	323	-13	318	-10	292	-20
Avastin	324	-15	330	-18	289	-19	290	-17	274	-15
Gazyva	213	16	232	15	225	8	240	25	249	15
Xofluza	47	185	21	178	31	362	53	-6	159	234
Pulmozyme	112	-6	113	2	104	4	126	18	123	10
Tamiflu	63	-29	24	19	26	9	29	-59	100	56

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Ocrevus	1,180	5	1,231	6	1,229	9	1,179	0	1,247	3
Hemlibra	592	-1	639	3	675	12	748	20	610	0
Vabysmo	650	91	721	68	775	49	794	35	718	7
Tecentriq	436	-9	462	-7	427	-8	438	-5	411	-8
Perjeta	343	-7	351	-6	335	1	316	35	342	-3
Xolair	496	10	614	11	627	12	733	29	645	26
Actemra/RoActemra	278	-1	317	13	354	19	382	12	294	3
Phesgo	126	36	132	18	146	34	166	64	179	38
Kadcyla	186	-1	195	3	193	8	191	2	201	5
Evrysdi	135	16	148	13	146	18	159	29	160	15
Alecensa	104	4	132	14	136	16	153	23	130	21
Polivy	117	166	138	80	155	50	158	45	156	30
MabThera/Rituxan	204	-21	218	-17	193	-14	227	2	181	-14
Activase/TNKase	282	4	279	-9	289	11	290	16	285	-2
Herceptin	67	-22	71	-16	63	-22	64	-12	60	-12
Avastin	99	-22	100	-18	90	-20	94	-17	80	-21
Gazyva	100	7	117	22	116	16	130	34	131	27
Xofluza	4	257	-	-78	1	-11	31	235	14	239
Pulmozyme	66	-15	75	-2	72	3	90	23	84	22
Tamiflu	-	-89	-	*	-	-	-8	-	9	*

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Ocrevus	310	8	329	15	322	11	345	21	344	11
Hemlibra	231	17	237	12	222	3	236	15	247	7
Vabysmo	138	224	149	153	167	104	168	88	197	42
Tecentriq	210	12	219	8	220	-3	214	0	220	5
Perjeta	171	-19	170	-12	161	-19	144	-9	144	-16
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	188	1	175	-8	145	-26	150	-21	152	-19
Phesgo	169	55	185	47	189	33	195	32	199	18
Kadcyla	145	-2	143	0	140	-5	136	5	135	-7
Evrysdi	137	27	149	16	149	13	137	3	145	6
Alecensa	72	3	73	-1	72	0	67	-5	68	-6
Polivy	54	42	32	-23	56	2	50	38	94	74
MabThera/Rituxan	39	-20	38	-14	32	-29	41	6	35	-10
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	77	-17	77	-12	73	-16	76	-6	77	0
Avastin	21	-27	23	-14	19	-9	22	13	14	-33
Gazyva	62	17	61	9	62	-1	60	11	60	-3
Xofluza	-	-65	-	0	-	50	-	386	-	*
Pulmozyme	20	0	19	3	16	-11	18	-2	18	-9
Tamiflu	12	33	2	-46	3	125	5	-30	26	114

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	79	2	92	4	88	4	108	22	82	3
Vabysmo	23	33	30	38	33	40	39	46	32	35
Tecentriq	86	-4	96	0	95	0	103	2	81	-5
Perjeta	36	-19	30	-39	26	-48	24	-53	18	-51
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	68	5	78	9	79	11	84	11	71	5
Phesgo	19	-	31	-	38	-	48	*	40	115
Kadcyla	21	-4	25	8	25	7	27	10	21	-3
Evrysdi	20	13	24	16	22	2	27	9	20	0
Alecensa	43	3	53	5	48	2	54	4	49	12
Polivy	44	2	48	-5	51	-9	55	-3	44	2
MabThera/Rituxan	4	-20	5	-26	3	-30	5	-22	3	-17
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	4	-41	4	-48	3	-56	3	-57	2	-56
Avastin	51	-33	51	-34	47	-32	48	-28	36	-30
Gazyva	6	-19	9	-14	6	-17	8	-10	8	46
Xofluza	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	27	-	24	1	2	-	32	-	-26
Tamiflu	7	-77	1	35	3	-14	15	-32	13	81

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024
Ocrevus	168	28	141	27	146	23	164	37	187	16
Hemlibra	138	51	135	16	152	64	131	36	226	72
Vabysmo	36	397	47	281	47	180	47	63	71	101
Tecentriq	133	34	156	30	163	32	182	5	158	21
Perjeta	386	14	434	14	366	25	323	9	336	-9
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	84	-15	88	32	94	52	81	26	102	26
Phesgo	74	165	63	75	72	87	87	129	175	142
Kadcyla	131	19	153	27	137	20	150	25	149	21
Evrysdi	64	-29	161	169	91	8	62	-9	95	56
Alecensa	136	5	153	15	129	4	123	4	150	12
Polivy	35	181	45	72	42	42	41	70	64	80
MabThera/Rituxan	104	-11	94	-12	89	-7	83	-11	79	-23
Activase/TNKase	14	7	18	25	13	-16	17	5	12	-9
Herceptin	216	-14	224	6	184	-6	175	-9	153	-29
Avastin	153	3	156	-11	133	-14	126	-16	144	-3
Gazyva	45	47	45	14	41	7	42	31	50	11
Xofluza	43	180	21	194	30	454	22	-53	145	234
Pulmozyme	26	22	19	17	15	32	18	18	21	-10
Tamiflu	44	-6	21	29	20	7	17	-61	52	17

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others